Clearmind Medicine Inc.'s SEC filings document foreign private issuer reports for a clinical-stage biotech developing non-hallucinogenic, neuroplastogen-derived psychedelic therapeutics. Form 6-K reports furnish press releases on CMND-100, MEAI-based Alcohol Use Disorder clinical development, European patent activity for PTSD compounds, and communications tied to FDA regulatory pathways.
The filings also record capital-structure matters, including securities purchase agreements, convertible promissory notes, conversions into common shares and amendments to financing capacity. Governance disclosures cover board composition, committee assignments and Nasdaq independence determinations, while incorporated registration statements on Form F-3 and Form S-8 connect current reports to the company's securities registration record.
Clearmind Medicine Inc. (NASDAQ: CMND) filed a Form 6-K for June 2025. The filing mainly furnishes a press release dated 27 June 2025 entitled “Clearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market.”
Key points disclosed:
- The company is expanding its global clinical trial program aimed at Alcohol Use Disorder (AUD), a market the company characterises as multibillion-dollar.
- The first four paragraphs of the press release are automatically incorporated by reference into Clearmind’s effective shelf registration statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and its equity incentive Form S-8 (File No. 333-283695).
- No financial metrics, study data, or timelines are provided in the filing itself.
- The document is informational only; it does not request shareholder action nor announce financing.
The 6-K was signed by CEO Adi Zuloff-Shani on 27 June 2025.
Clearmind Medicine Inc. (CMND) has filed a Form 6-K for June 2025.
The filing mainly furnishes a press release dated 23 June 2025 entitled “Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder.” No financial statements, earnings data, or transactional details accompany the report. The company simply notifies investors that the first two paragraphs of the press release are incorporated by reference into several existing U.S. registration statements on Forms F-3 (File Nos. 333-275991, 333-270859, 333-273293) and S-8 (File No. 333-283695).
The filing is signed by CEO Adi Zuloff-Shani on 23 June 2025. Aside from the clinical-site expansion disclosure, there are no other material events, financial metrics, or risk factors discussed.